Effect of low-dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block.
BACKGROUND
The purpose of this study was to compare the onset and duration of sensory and motor block, as well as the hemodynamic changes and level of sedation, following intrathecal bupivacaine supplemented with either dexmedetomidine or clonidine.


METHODS
In a prospective, double-blind study, 60 patients undergoing transurethral resection of prostate or bladder tumor under spinal anesthesia were randomly allocated to one of three groups. Group B received 12 mg of hyperbaric bupivacaine, group D received 12 mg of bupivacaine supplemented with 3 microg of dexmedetomidine and group C received 12 mg of bupivacaine supplemented with 30 microg of clonidine. The onset times to reach peak sensory and motor levels, and the sensory and motor regression times, were recorded. Hemodynamic changes and the level of sedation were also recorded.


RESULTS
Patients in groups D and C had a significantly shorter onset time of motor block and significantly longer sensory and motor regression times than patients in group B. The mean time of sensory regression to the S1 segment was 303 +/- 75 min in group D, 272 +/- 38 min in group C and 190 +/- 48 min in group B (B vs. D and B vs. C, P < 0.001). The regression of motor block to Bromage 0 was 250 +/- 76 min in group D, 216 +/- 35 min in group C and 163 +/- 47 min in group B (B vs. D and B vs. C, P < 0.001). The onset and regression times were not significantly different between groups D and C. The mean arterial pressure, heart rate and level of sedation were similar in the three groups intra-operatively and post-operatively.


CONCLUSIONS
Dexmedetomidine (3 microg) or clonidine (30 microg), when added to intrathecal bupivacaine, produces a similar prolongation in the duration of the motor and sensory block with preserved hemodynamic stability and lack of sedation.
Kanazi
G E
GE
Department of Anesthesiology, American University of Beirut-Medical Center, Beirut, Lebanon. gk05@aub.edu.lb
Aouad
M T
MT
Jabbour-Khoury
S I
SI
Al Jazzar
M D
MD
Alameddine
M M
MM
Al-Yaman
R
R
Bulbul
M
M
Baraka
A S
AS
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000368:Aged; D000704:Analysis of Variance; D000775:Anesthesia, Spinal / Q000379:methods*; D019162:Anesthetics, Combined / Q000008:administration & dosage / Q000494:pharmacology; D000779:Anesthetics, Local / Q000008:administration & dosage / Q000494:pharmacology; D002045:Bupivacaine / Q000008:administration & dosage / Q000494:pharmacology*; D003000:Clonidine / Q000494:pharmacology*; D016292:Procedural Sedation / Q000379:methods; D020927:Dexmedetomidine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004357:Drug Synergism; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D009407:Nerve Block / Q000379:methods*; D010147:Pain Measurement / Q000379:methods; D011446:Prospective Studies; D013997:Time Factors; D014565:Urogenital Neoplasms / Q000601:surgery*
D000316:Adrenergic alpha-Agonists; D019162:Anesthetics, Combined; D000779:Anesthetics, Local; D020927:Dexmedetomidine; D003000:Clonidine; D002045:Bupivacaine